Es gab 50 kürzliche Insider-Transaktionen für Xilio Therapeutics, Inc. (XLO), darunter 36 Käufe und 11 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $14.86M und die gesamten Insider-Verkäufe auf $12.1M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Shannon James Samuel, Gilead Sciences, Inc., Brennan Kevin M.. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — XLO
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-03-26 |
Shannon James Samuel |
Director |
Informierter Kauf |
5,000 |
$8.79 |
$43.95K |
10,000 |
| 2026-02-13 |
Gilead Sciences, Inc. |
10 Percent Owner |
Informierter Kauf |
3,739,000 |
$0.00 |
$373.90 |
40,384,266 |
| 2026-01-02 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Informierter Verkauf |
1,826 |
$0.64 |
$1.17K |
6,371 |
| 2026-01-02 |
Frankenfield Christopher James |
Chief Financial Officer |
Informierter Verkauf |
7,030 |
$0.64 |
$4.52K |
24,766 |
| 2026-01-01 |
Russo Rene |
President and CEO |
Optionsausübung (Verkauf) |
44,250 |
- |
- |
88,500 |
| 2026-01-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Optionsausübung |
5,000 |
- |
- |
8,197 |
| 2026-01-01 |
Frankenfield Christopher James |
Chief Financial Officer |
Optionsausübung |
19,375 |
- |
- |
31,796 |
| 2026-01-01 |
Luptakova Katarina |
Chief Medical Officer |
Optionsausübung |
16,625 |
- |
- |
33,250 |
| 2025-12-31 |
Russo Rene |
President and CEO |
RSU-Zuteilung |
1,500,258 |
$0.84 |
$1.26M |
1,500,258 |
| 2025-12-31 |
Brennan Kevin M. |
SVP, Finance and Accounting |
RSU-Zuteilung |
95,221 |
$0.84 |
$80.08K |
95,221 |
| 2025-12-31 |
Frankenfield Christopher James |
Chief Financial Officer |
RSU-Zuteilung |
668,789 |
$0.84 |
$562.45K |
668,789 |
| 2025-12-31 |
Luptakova Katarina |
Chief Medical Officer |
RSU-Zuteilung |
451,885 |
$0.84 |
$380.04K |
451,885 |
| 2025-11-26 |
Gilead Sciences, Inc. |
10 Percent Owner |
Optionsausübung (ITM) |
13,335,000 |
$0.75 |
$10M |
- |
| 2025-11-21 |
Russo Rene |
President and CEO |
Aktienrückgabe |
135,134 |
$11.69 |
$1.58M |
- |
| 2025-11-21 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Aktienrückgabe |
20,000 |
$1.08 |
$21.6K |
- |
| 2025-11-21 |
Frankenfield Christopher James |
Chief Financial Officer |
Aktienrückgabe |
150,000 |
$2.75 |
$412.5K |
- |
| 2025-11-21 |
Luptakova Katarina |
Chief Medical Officer |
Aktienrückgabe |
25,000 |
$2.79 |
$69.63K |
- |
| 2025-06-17 |
Shannon James Samuel |
Director |
Informierter Kauf |
25,000 |
$0.69 |
$17.22K |
70,000 |
| 2025-06-16 |
Shannon James Samuel |
Director |
Informierter Kauf |
45,000 |
$0.69 |
$30.87K |
45,000 |
| 2025-06-16 |
Russo Rene |
President and CEO |
Informierter Kauf |
36,289 |
$0.68 |
$24.68K |
281,172 |
| 2025-06-11 |
Clancy Paul J |
Director |
RSU-Zuteilung |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Shannon James Samuel |
Director |
RSU-Zuteilung |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Bonstein Sara |
Director |
RSU-Zuteilung |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Brennan Aoife |
Director |
RSU-Zuteilung |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Ross Robert W. |
Director |
RSU-Zuteilung |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Rossi Christina |
Director |
RSU-Zuteilung |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Xu Yuan |
Director |
RSU-Zuteilung |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-11 |
Curran Daniel J. |
Director |
RSU-Zuteilung |
31,000 |
$0.69 |
$21.48K |
31,000 |
| 2025-06-10 |
Bello Akintunde Olatokumbo |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2025-06-10 |
Bello Akintunde Olatokumbo |
Director |
RSU-Zuteilung |
62,000 |
$0.70 |
$43.4K |
62,000 |
| 2025-06-05 |
Gilead Sciences, Inc. |
10 Percent Owner |
Informierter Kauf |
13,335,000 |
$0.75 |
$10M |
13,335,000 |
| 2025-04-15 |
Russo Rene |
President and CEO |
RSU-Zuteilung |
190,000 |
$0.71 |
$135.28K |
190,000 |
| 2025-04-15 |
Frankenfield Christopher James |
Chief Financial Officer |
RSU-Zuteilung |
75,000 |
$0.71 |
$53.4K |
75,000 |
| 2025-01-02 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Informierter Verkauf |
1,803 |
$0.98 |
$1.77K |
3,197 |
| 2025-01-02 |
Frankenfield Christopher James |
Chief Financial Officer |
Informierter Verkauf |
6,954 |
$0.98 |
$6.84K |
12,421 |
| 2025-01-01 |
Russo Rene |
President and CEO |
Optionsausübung (Verkauf) |
44,250 |
- |
- |
132,750 |
| 2025-01-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
Optionsausübung |
5,000 |
- |
- |
5,000 |
| 2025-01-01 |
Frankenfield Christopher James |
Chief Financial Officer |
Optionsausübung |
19,375 |
- |
- |
19,375 |
| 2025-01-01 |
Luptakova Katarina |
Chief Medical Officer |
Optionsausübung |
16,625 |
- |
- |
16,625 |
| 2025-01-01 |
Russo Rene |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2024-12-18 |
Gilead Sciences, Inc. |
10 Percent Owner |
Informierter Kauf |
1,759,978 |
$1.04 |
$1.83M |
9,105,451 |
| 2024-10-01 |
Brennan Kevin M. |
SVP, Finance and Accounting |
RSU-Zuteilung |
26,000 |
$0.75 |
$19.5K |
26,000 |
| 2024-08-03 |
Frankenfield Christopher James |
Chief Operating Officer |
RSU-Zuteilung |
52,000 |
$0.90 |
$46.54K |
52,000 |
| 2024-06-14 |
Clancy Paul J |
Director |
RSU-Zuteilung |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Bonstein Sara |
Director |
RSU-Zuteilung |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Ross Robert W. |
Director |
RSU-Zuteilung |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Rossi Christina |
Director |
RSU-Zuteilung |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Xu Yuan |
Director |
RSU-Zuteilung |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-14 |
Curran Daniel J. |
Director |
RSU-Zuteilung |
25,000 |
$1.02 |
$25.5K |
25,000 |
| 2024-06-13 |
Shannon James Samuel |
Officer |
Unbekannt |
- |
- |
- |
- |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
